Healthcare provider profile · identity verified

Niharika Sathe, MD

Internal Medicine · CAMDEN, NJ · NPI 1255780599

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	680	152
Amlodipine Besylate	Amlodipine Besylate	407	118
Lisinopril	Lisinopril	228	63
Albuterol Sulfate Hfa	Albuterol Sulfate	205	57
Metformin Hcl	Metformin Hcl	200	55
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	198	29
Rosuvastatin Calcium	Rosuvastatin Calcium	167	56
Gabapentin	Gabapentin	165	53
Omeprazole	Omeprazole	159	38
Losartan Potassium	Losartan Potassium	142	41
Pantoprazole Sodium	Pantoprazole Sodium	139	48
Levothyroxine Sodium	Levothyroxine Sodium	132	30
Chlorthalidone	Chlorthalidone	130	44
Fluticasone Propionate	Fluticasone Propionate	115	41
Jardiance	Empagliflozin	99	21
Metformin Hcl Er	Metformin Hcl	93	27
Tamsulosin Hcl	Tamsulosin Hcl	91	26
Diclofenac Sodium	Diclofenac Sodium	86	29
Trulicity	Dulaglutide	86	15
Triumeq	Abacavir/Dolutegravir/Lamivudi	85	11
Famotidine	Famotidine	79	25
Carvedilol	Carvedilol	76	24
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	68	17
Metoprolol Succinate	Metoprolol Succinate	64	25
Eliquis	Apixaban	60	18
Hydrochlorothiazide	Hydrochlorothiazide	60	22
Montelukast Sodium	Montelukast Sodium	60	13
Tivicay	Dolutegravir Sodium	59	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	55	15
Mirtazapine	Mirtazapine	53	13
Duloxetine Hcl	Duloxetine Hcl	49	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	46	13
Ozempic	Semaglutide	46	suppressed
Alendronate Sodium	Alendronate Sodium	45	suppressed
Incruse Ellipta	Umeclidinium Bromide	45	suppressed
Allopurinol	Allopurinol	42	11
Trazodone Hcl	Trazodone Hcl	42	16
Ibuprofen	Ibuprofen	40	23
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	39	suppressed
Pregabalin	Pregabalin	36	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	35	suppressed
Farxiga	Dapagliflozin Propanediol	33	suppressed
Varenicline Tartrate	Varenicline Tartrate	31	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	11
Valsartan	Valsartan	29	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	27	12
Glipizide	Glipizide	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Furosemide	Furosemide	26	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	25	suppressed
Ketoconazole	Ketoconazole	23	14
Sertraline Hcl	Sertraline Hcl	23	13
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Valacyclovir	Valacyclovir Hcl	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Estradiol	Estradiol	21	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Vascepa	Icosapent Ethyl	21	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	20	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	20	suppressed
Oxycodone Hcl	Oxycodone Hcl	20	suppressed
Prezcobix	Darunavir/Cobicistat	20	suppressed
Abacavir-Lamivudine	Abacavir Sulfate/Lamivudine	19	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	19	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	19	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Insulin Lispro	Insulin Lispro	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Ammonium Lactate	Ammonium Lactate	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	16	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	16	suppressed
Juluca	Dolutegravir/Rilpivirine	16	suppressed
Topiramate	Topiramate	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Atenolol	Atenolol	15	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	15	suppressed
Lidocaine	Lidocaine	15	suppressed
Propranolol Hcl	Propranolol Hcl	15	suppressed
Bydureon Bcise	Exenatide Microspheres	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Dovato	Dolutegravir Sodium/Lamivudine	13	suppressed
Finasteride	Finasteride	13	suppressed
Humalog	Insulin Lispro	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Levemir	Insulin Detemir	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	12	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Cholestyramine Light	Cholestyramine	11	suppressed
Clonidine	Clonidine	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Naproxen	Naproxen	11	suppressed
Prednisone	Prednisone	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error